Cardiology
HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch Aimed at Ischemia Detection
HeartBeam Inc. has initiated a pilot study for its investigational on-demand 12-lead ECG patch in coronary artery disease patients, potentially expanding ambulatory cardiac monitoring into ischemia detection within a $2 billion market.
HeartBeam Expands Concierge Cardiology Footprint with Atelier Health Agreement
HeartBeam Inc. has signed a commercial agreement with Beverly Hills-based Atelier Health, expanding its launch footprint into Southern California and completing its initial targeted markets for its cable-free 3D ECG technology.
HeartBeam Targets Heart Disease with Advanced ECG Technology as Cardiovascular Deaths Surge
HeartBeam Inc. is developing next-generation ECG solutions to address the gap in early cardiac detection, as cardiovascular disease remains the leading cause of death in the U.S. with over 919,000 deaths in 2023.
New Book Aims to Close Awareness Gap on Women's Heart Disease Symptoms
Cardiologist Arash Bereliani releases 'What About Her Heart' to educate the public on how heart disease presents differently in women, addressing a critical gap in recognition and timely diagnosis.
Ventripoint to Showcase AI-Powered Cardiac Imaging at European Paediatric Cardiology Conference
Ventripoint will exhibit its VMS+ 4.0 technology at the AEPC annual meeting, highlighting its potential to improve lifelong care for congenital heart disease patients through accurate, MRI-equivalent assessments from echocardiograms.
Cardio Diagnostics Harnesses AI and Biomarkers to Combat Heart Disease Burden
Cardio Diagnostics Holdings is advancing early detection of cardiovascular disease using an AI-powered platform that analyzes epigenetic and genetic biomarkers from a simple blood sample, addressing the leading cause of death in the U.S.
Cardio Diagnostics Targets Precision Cardiology with Multi-Omic AI Platform
Cardio Diagnostics Holdings (NASDAQ: CDIO) leverages AI to integrate epigenetic and genetic biomarkers for personalized cardiovascular risk assessments, potentially transforming disease prevention and treatment.
Ventripoint's AI-Powered Cardiac Imaging System Submitted for Expedited Approval in China
Ventripoint Diagnostics announced that its VMS+ 4.0 system has been submitted for regulatory approval in China via an expedited 'green channel' pathway, potentially accelerating access to AI-driven cardiac diagnostics in a market with 330 million cardiovascular patients.
Advanced Heart, Kidney and Metabolic Syndrome Linked to 30% Higher Cancer Risk, Study Finds
New research published in Circulation: Population Health and Outcomes reveals that later stages of cardiovascular-kidney-metabolic (CKM) syndrome are associated with a 25-30% increased risk of cancer, highlighting the need for integrated screening.
HeartBeam Partners with Mount Sinai to Develop AI-Driven ECG Algorithms
HeartBeam's collaboration with Mount Sinai aims to advance AI-enabled ECG analysis, reinforcing its role in the shift toward data-driven remote cardiac monitoring.
HeartBeam Partners with Mount Sinai to Develop AI-Powered ECG Algorithms
HeartBeam Inc. collaborates with Mount Sinai to advance AI-driven ECG technology, aiming to enhance remote cardiac monitoring and chronic condition management.
American Heart Association Mourns Passing of Pioneering Cardiologist Eugene Braunwald
The American Heart Association honors the legacy of Dr. Eugene Braunwald, whose seven decades of research transformed cardiovascular medicine, and highlights his enduring influence through mentorship and the Eugene Braunwald Academic Mentorship Award.
HeartBeam Announces Public Offering to Fund Cardiac Technology Commercialization and AI Development
HeartBeam Inc. is launching a public offering to finance the commercialization of its FDA-cleared 12-lead ECG system and advance AI initiatives for cardiac care.
HeartBeam Closes $10 Million Public Offering to Accelerate Cardiac Tech Commercialization
HeartBeam Inc. raised $10 million in a public offering to fund the commercialization of its FDA-cleared 12-lead synthesized ECG system and other cardiac technologies.
HeartBeam Closes $10M Public Offering to Fund Commercialization of ECG Technology
HeartBeam raised $10 million in a public offering to advance its FDA-cleared 12-lead synthesized ECG system and heart attack detection technologies, positioning the company for expanded market reach.
BioXgen Seeks Crowdfunding Investment for Cardiac Patch Targeting Post-Surgery Complication
BioXgen is launching a Regulation Crowdfunding investment round and hosting a webinar to demonstrate its cardiac patch designed to prevent postoperative atrial fibrillation, a common complication affecting nearly half of open-heart surgery patients.
HeartBeam Partners with HeartNexus to Expand Remote Cardiac Diagnostic Access
HeartBeam's collaboration with HeartNexus enables 24/7 cardiologist access for remote ECG interpretation, addressing critical gaps in cardiovascular care accessibility worldwide.
Polypill Strategy Shows Promise for Heart Failure Treatment, Improving Outcomes and Medication Adherence
A new study demonstrates that a once-daily combination pill for heart failure patients significantly improves heart function, reduces hospitalizations, and enhances quality of life compared to traditional multi-pill regimens.
PCSK9 Inhibitor Combined with Statin Shows Significant LDL Reduction in Heart Transplant Patients
A clinical trial demonstrates that adding the PCSK9 inhibitor alirocumab to statin therapy reduces LDL cholesterol by more than 50% in heart transplant patients, though it did not prevent the development of cardiac allograft vasculopathy.
Stress Cardiac MRI Testing Improves Angina Diagnosis and Patient Outcomes, Study Finds
New research presented at the American Heart Association's Scientific Sessions 2025 demonstrates that stress cardiac MRI testing significantly improves diagnosis accuracy and quality of life for patients with chest pain despite clear coronary arteries.
Study Finds Prasugrel May Offer Better Outcomes Than Ticagrelor for Diabetic Patients With Stents
New research presented at the American Heart Association's Scientific Sessions 2025 suggests prasugrel may be more effective than ticagrelor at preventing heart attacks, strokes, bleeding complications and death in diabetic patients who received coronary stents, challenging current interchangeable use of these antiplatelet medications.
Tailored Vitamin D Doses Reduce Heart Attack Risk by 52% in Heart Disease Patients
Adults with heart disease who received personalized vitamin D supplementation to achieve optimal blood levels experienced more than half the risk of heart attack compared to those without vitamin D monitoring, according to preliminary research presented at the American Heart Association's Scientific Sessions 2025.
Daily Coffee Consumption Linked to Reduced AFib Recurrence in New Clinical Trial
A new clinical trial reveals that adults with atrial fibrillation who drank one cup of coffee daily were 39% less likely to experience recurrent AFib episodes, challenging conventional medical advice about caffeine avoidance for heart rhythm patients.
Earlier Blood Transfusions May Reduce Heart Failure Risk in Cardiac Patients After Surgery
A new study suggests that transfusing blood earlier in patients with heart disease undergoing major surgery may significantly reduce the risk of heart failure and irregular heartbeat without increasing severe complication rates.
Catheter Ablation May Eliminate Need for Blood Thinners in Some AFib Patients, Study Finds
New research suggests successful catheter ablation for atrial fibrillation reduces stroke risk enough that many patients can safely discontinue potent blood thinners in favor of aspirin, potentially reducing bleeding complications while maintaining stroke protection.
Shorter Clot-Prevention Therapy After Stent Placement Proves Effective for AFib Patients
New research shows a one-month course of dual clot-preventing therapy followed by single medication treatment is as effective as year-long dual therapy for preventing stroke, heart attack and death in atrial fibrillation patients with stents, while significantly reducing bleeding complications.
Standard Medical Care Outperforms Minimally Invasive Procedure for High-Risk Atrial Fibrillation Patients
New research presented at the American Heart Association's Scientific Sessions 2025 found that standard medical care, including blood thinners when appropriate, proved more effective than a catheter-based procedure for preventing stroke and other complications in older atrial fibrillation patients at high risk of bleeding and stroke.
HeartBeam Submits Breakthrough ECG Technology for FDA Clearance
HeartBeam Inc. has submitted its innovative 12-lead ECG synthesis software to the FDA for clearance, representing a significant advancement in cardiac arrhythmia detection and management.
HeartBeam Receives Buy Rating and $4 Price Target from Roth Capital, Highlighting FDA Clearance Catalyst
HeartBeam Inc. received a Buy rating and $4 price target from Roth Capital, which emphasized the company's potential FDA clearance for its 12-lead ECG synthesis software and its position to transform remote cardiac monitoring.
American Heart Association Launches Initiative to Accelerate Aortic Stenosis Diagnosis and Clinical Trial Access
The American Heart Association has launched a new initiative to improve early diagnosis of aortic stenosis and increase participation in clinical trials, potentially transforming care for this serious heart condition that often goes undiagnosed until advanced stages.